Pharmaceutical Technology

AUGUST 14, 2024

As part of pipeline reprioritisation, Acelyrin has dropped izokibep and will instead start Phase III trials for lonigutamab in Q1 2025.

Leads 52

Leads 52

European Pharmaceutical Review

NOVEMBER 21, 2023

If successful this could lead to regulatory submissions in 2025, supporting the health of asthma and COPD patients and making a significant positive impact on our transition to a more environmentally sustainable future,” GSK’s Chief Executive Officer, Emma Walmsley commented.

Manufacturing 116

Manufacturing Patients Pharma Leads 116

Pharmaceutical Technology

JUNE 7, 2023

Eli Lilly has achieved significant gains in the past quarter, leading to it becoming the most valuable pharmaceutical company in the world, with a market cap of $420bn, surpassing Johnson & Johnson. There have been several Phase III trials for Mounjaro, with SURMOUNT-1 demonstrating a weight loss of up to 22.5%

Leads 98

Leads Marketing FDA Sales 98

pharmaphorum

NOVEMBER 9, 2022

A recent report from GlobalData noted that AI is being used to enhance computer-aided drug design (CADD) in a bid to reduce the time and costs involved in getting new drugs to market, and predicted that pharma spending on AI drug discovery would hit $3 billion in 2025. Its lead indication is idiopathic pulmonary fibrosis. The Pharma.AI

Pharma 111

Pharma Leads Marketing Medicine 111

Pharmaceutical Technology

JUNE 7, 2024

The facility is expected to allow Orano Med to produce 5,000 doses of lead-212 based radioligand therapies by 2025.

Manufacturing 52

Manufacturing Leads 52

Pharmaceutical Technology

APRIL 8, 2024

Sensorion expects results from a Phase I/II trial of its lead candidate SENS-501 in the second half of 2025.

Leads 52

Leads 52

Pharmaceutical Technology

SEPTEMBER 5, 2022

Until 2025, we have strong growth ahead of us, but we also believe we can continue to grow very strongly post-2025 and it’s all about innovation in the pipeline.”. On 23 August, at a Reuters Newsmakers online forum, Soriot announced his interest in increasing AstraZeneca’s portfolio of bolt-on acquisitions leading up to 2025.

FDA 114

FDA Pharmaceutical Biopharma Pharma 114

Pharmaceutical Technology

DECEMBER 21, 2022

Planned to be operational by 2025, the construction of the facility is anticipated to begin early next year. Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer.

Government 140

Government Manufacturing Pharmaceutical Marketing 140

European Pharmaceutical Review

OCTOBER 22, 2024

The agency anticipated that the regulation could become law in Summer 2025. Introduction of this framework was originally announced by the MHRA in January 2023. It follows a consultation with stakeholders in 2021, which resulted in great support for proposals for a framework focused on point of care and modular manufacturing.

Medicine 89

Medicine Manufacturing Safety Consulting 89

European Pharmaceutical Review

SEPTEMBER 26, 2022

The €60 million expansion will open 70 new jobs in sterile manufacturing, quality control and engineering in 2025. to lead R&D organization and drive continued pipeline advancement… The post AbbVie Cork facility €60 million expansion appeared first on European Pharmaceutical Review. AbbVie announces Michael Severino, M.D.

Manufacturing 98

Manufacturing Pharmaceutical manufacturing Biopharma Engineering 98

European Pharmaceutical Review

AUGUST 1, 2022

Therefore, it is essential that we broaden the scope of medical trials and research,” commented Tinamarie Duff, DAWN Global People & Business Resource Group Lead. Common clinical trial practices exclude up to a quarter of the US population based on disability status, according to BMS.

Food and Drug Administration 122

Food and Drug Administration Medical Medicine Engineering 122

European Pharmaceutical Review

DECEMBER 3, 2024

“PTC518 is the leading oral disease-modifying therapy in development for Huntington’s disease and the economics of this agreement are consistent with the promise of this treatment,” stated Dr Matthew Klein, Chief Executive Officer, PTC Therapeutics.

Biopharma 59

Biopharma Leads Pharmaceutical Manufacturing 59

pharmaphorum

JANUARY 9, 2023

Supported by voting agreements from leading Amryt shareholders and directors, and unanimously approved and recommended by the boards of both companies, the total transaction is worth up to $1.48 Biopharma and healthcare group Chiesi Farmaceutici S.p.A. is to acquire the 2015-established Amryt Pharma Plc. in an all-cash transaction at $14.50

Pharma 98

Pharma Biopharma Management Medicine 98

European Pharmaceutical Review

NOVEMBER 23, 2023

For example, CPI asserted that lead times for clinical trial materials are hindering new therapies being developed. CPI confirmed that the centre will establish operations during 2024 and be finished in late 2025. This is a first-of-its-kind collaboration for the pharma industry.

Manufacturing 104

Manufacturing Medicine Government Pharmaceutical 104

European Pharmaceutical Review

NOVEMBER 21, 2024

Dr Boshoff will begin this new role on 1 January 2025 and will oversee all R&D functions across every therapeutic area in the company. Furthermore, Dr Roger Dansey will become Interim Chief Oncology Officer, from 1 January 2025. Dr Johanna Bendell from Roche is set to be Pfizer’s Chief Development Officer, Oncology from 2025.

Medicine 59

Medicine Medical science Biopharma Medical 59

European Pharmaceutical Review

MARCH 6, 2023

Harwell, the UK’s leading science and innovation campus in Oxfordshire will be the location of the Moderna Innovation and Technology Centre (MITC). The Moderna Innovation and Technology Centre is expected to become operational in 2025. Moderna is the latest organisation to join Harwell’s Health Tech cluster.

Manufacturing 98

Manufacturing Food and Drug Administration Government Food 98

Nixon Gwilt Law

MARCH 19, 2024

Download the 8 Guiding Principles for AI-Driven Digital Health now!

Government 52

Government Leads 52

Nixon Gwilt Law

MARCH 19, 2024

Download the 8 Guiding Principles for AI-Driven Digital Health now!

Government 52

Government Leads 52

pharmaphorum

SEPTEMBER 21, 2022

The European Commission has followed the lead of the US FDA and approved AstraZeneca’s Tezspire as an add-on maintenance therapy for patients with severe asthma, becoming the first and only biologic that can be used in all patients, and not restricted to those with specific forms of the disease. billion or more.

Sales 111

Sales Patients Medicine Biopharma 111

Pharmaceutical Technology

APRIL 17, 2023

The proposed merger is expected to realise at least $50m of net transaction cash proceeds, set to be used to finance the merged entity’s business as well as Phase II trials and operations through the second quarter of 2025. The merger is scheduled to be completed by the third quarter of 2023.

Patients 98

Patients Leads Pharmaceutical Marketing 98

pharmaphorum

OCTOBER 26, 2022

The drug was highlighted at Boehringer’s R&D update earlier this year as one of the most promising candidates among 15 new medicines it plans to bring to market by 2025, fuelled by a €25 billion R&D spend. There are more than 200 lung disorders that can lead to pulmonary fibrosis.

Recruitment 98

Recruitment Prospecting Marketing Patients 98

PM360

OCTOBER 25, 2023

According to a report by McKinsey & Company, the medical affairs function is on track to rise in importance, becoming the third strategic pillar alongside the research and development (R&D) and commercial functions by 2025. This lack of understanding may lead to resistance or wariness of new technology. Regulatory concerns.

Management 105

Management Medical Pharma Pharmaceutical 105

European Pharmaceutical Review

DECEMBER 18, 2024

Detailed findings of this study are set to be presented at a scientific forum in 2025, according to Sanofi and Teva. Teva and Sanofis duvakitug partnership In a collaborative effort to develop Tevas duvakitug as a treatment for ulcerative colitis and Crohns disease, Sanofi will lead the Phase III clinical development programme.

Leads 52

Leads Pharmaceutical Medicine Patients 52

Curzon Consulting

OCTOBER 17, 2024

Last Friday, Curzon representatives Nigel Brannan, and AMBS Alumni Sarbo Saha, and Aziz Yuldashev, joined the group and were introduced to the students, leading them through an interactive case study session. The students now have a few months of preparation before the preliminary rounds begin in January 2025.

Competition 52

Competition Consulting Recruitment Government 52

pharmaphorum

AUGUST 17, 2022

The deal will see Atomwise identify, synthesize, and advance lead compounds for up to five drug targets that will then be exclusively Sanofi’s to develop. A recent report from GlobalData predicted that pharma spending on AI drug discovery would hit $3 billion in 2025.

Medicine 97

Medicine Pharma Engineering Sales 97

Pharmaceutical Technology

NOVEMBER 1, 2022

Israel, another leading adopter, has a thriving EHR technology industry that is adapting to the country’s widespread use of Big Data from its country’s healthcare systems. This includes issues related to drug shortages and research into new therapeutics, which will be addressed in the EMA’s strategy for 2025. “We

Electronics 111

Electronics Prescription Healthcare Healthcare 111

Pharmaceutical Technology

MAY 19, 2023

EyePoint Pharmaceuticals will also receive potential royalties on the combined net sales of Iluvien and Yutiq in the US from 2025 to 2028. EYP-1901 is an investigational sustained delivery intravitreal anti-VEGF treatment which is now being evaluated in Phase II clinical trials.

Food and Drug Administration 52

Food and Drug Administration Food Pharmaceutical Sales 52

pharmaphorum

OCTOBER 9, 2022

UK-based PureTech – which develops its own therapies and also has interests in a wide range of companies including digital health players Akili and Sonde as well as drug developers Vedanta, Gelesis and Follica – said it has “exchanged indicative, non-binding proposals” with Nektar that have no guarantee of leading to a deal.

Leads 59

Leads Healthcare Healthcare 59

Clarify Health

NOVEMBER 21, 2024

According to research from PwC, medical costs alone are projected to rise 7–8% in 2025 , marking the highest increase in over 13 years. Managing disparate platforms can be overwhelming, leading to increased workload and stress. Following record healthcare spending of $4.5

Healthcare 52

Healthcare Healthcare Leads Medical 52

PM360

SEPTEMBER 21, 2023

CMS negotiation may lead to additional savings for beneficiaries and for the Medicare program. Manufacturers will want to understand the changing plan economics under Part D redesign in addition to the coming effects from drug negotiation as they embark on contract negotiations for the 2025 plan year and beyond.

Manufacturing 111

Manufacturing Marketing Competition Physicians 111

pharmaphorum

OCTOBER 13, 2022

However, there is a problem facing the treatment of osteoporosis, and it is the lack of research into new therapies, leading to a limited pipeline of new treatments coming through. It is projected that this could lead to a situation where the economic burden would be “unsustainable for most healthcare systems,” he concluded.

Marketing 98

Marketing Healthcare Healthcare Leads 98

European Pharmaceutical Review

MARCH 14, 2024

This leads to the formation of immune complexes that deposit in the glomerulus and result in haematuria, proteinuria, and decline in kidney function. Topline data from Vera’s ORIGIN Phase III trial of atacicept is expected in the first half of 2025. IgAN is the most common primary glomerulonephritis worldwide.

Food and Drug Administration 98

Food and Drug Administration Patients Leads Side effects 98

European Pharmaceutical Review

MARCH 14, 2024

This leads to the formation of immune complexes that deposit in the glomerulus and result in haematuria, proteinuria, and decline in kidney function. Topline data from Vera’s ORIGIN Phase III trial of atacicept is expected in the first half of 2025. IgAN is the most common primary glomerulonephritis worldwide.

Food and Drug Administration 98

Food and Drug Administration Patients Leads Side effects 98

European Pharmaceutical Review

FEBRUARY 28, 2024

Starting in 2025, health technology assessment (HTA) experts from across Europe will join forces to produce joint clinical assessment (JCA) reports, which will be used to support national health economic assessments as well as inform pricing and reimbursement discussions.

Patients 97

Patients Ethics Healthcare Healthcare 97

pharmaphorum

JANUARY 10, 2023

Approximately 30% of global data volume is generated by the healthcare industry and it will continue to expand with a compound annual growth rate predicted to reach 36% by 2025, according to research by RBC Capital Markets. It flows from every direction in torrents to create huge opportunities to address the world’s mounting health issues.

Marketing 98

Marketing Pharma Healthcare Healthcare 98

Pharma Marketing Network

NOVEMBER 15, 2024

By understanding your audience, balancing content, engaging transparently, using influencers, and continuously analyzing performance, your social media strategy will be primed for success in 2025. What are the top platforms for pharma marketing in 2025? LinkedIn and Twitter are leading platforms for professional and medical content.

Media 52

Media Pharma Marketing Medical 52

European Pharmaceutical Review

NOVEMBER 7, 2024

percent between 2025 and 2030. Regional trends in the single-use technology rocking bioreactor market The report named the Americas as the leading region in the single-use technology rocking bioreactor market. A driving force for this was identified to be that the region benefits from having major bioreactor manufacturers.

Marketing 52

Marketing Manufacturing Medicine Leads 52